

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,719,976 B1  
APPLICATION NO. : 09/142524  
DATED : April 13, 2004  
INVENTOR(S) : Toshio Sone et al.

Page 1 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title Page:

Item 56, References Cited, Other Publications, Left Column, 4<sup>th</sup> reference, Taniai *et al*, "Taniai, Madoka, Shunsaku Ando, Mitsuko Usui, Masashi Kurimoto et al. (Nov. 1988) "N-terminal amino acid sequence of a major allergen of Japanese cedar pollen (Cry J 1)" *60 FEBS LETTERS* 239(2):329-332."

should read

-- Taniai, Madoka, Shunsaku Ando, Mitsuko Usui, Masashi Kurimoto et al. (Nov. 1988) "N-terminal amino acid sequence of a major allergen of Japanese cedar pollen (Cry j 1)" *FEBS LETTERS* 239(2):329-332. --

Title page:

Item 56, References Cited, Other Publications, Right Column, 3rd reference, Matsunaga *et al*, "Matsunaga, Youchi, Toshiji Saibara, Hiroshi Kido, Nobuhiko Katunuma (Jan. 1993) "Participation of cathepsin B in processing of antigen presentation to MHC class II" *FEBS LETTERS* 324(3):325-330."

should read

--Matsunaga, Youchi, Toshiji Saibara, Hiroshi Kido, Nobuhiko Katunuma (Jan. 1993) "Participation of cathepsin B in processing of antigen presentation to MHC class II" *FEBS LETTERS* 324(3):325-330.--

Title page:

Item 57, Abstract, Line 5 "multi-epitope peptide can treat a wide"

should read

--multi-epitope peptide can prevent and treat a wide--

Column 1:

Line 49 "βchain"

should read

-- β-chain --

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,719,976 B1  
APPLICATION NO. : 09/142524  
DATED : April 13, 2004  
INVENTOR(S) : Toshio Sone et al.

Page 2 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3:

Line 8 "77-36"

should read

--77-86--

Column 4:

Line 39 "for each, patient"

should read

--for each patient--

Column 4:

Line 60 "class It molecules"

should read

--class II molecules--

Column 5:

Line 8 "DPB1\*10.501"

should read

--DPB1\*0501--

Column 7:

Line 62 "(DRB1\*140)"

should read

--(DRB1\*1405)--

Column 8:

Line 10 "from BCGA antigen."

should read

--from BCGa antigen.--

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,719,976 B1  
APPLICATION NO. : 09/142524  
DATED : April 13, 2004  
INVENTOR(S) : Toshio Sone et al.

Page 3 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 8:

Line 54 "Brief Description of the Sequences" is missing and

should read

--Brief Description of the Sequences

SEQ ID NOs: 1-174 provide amino acid sequences for various peptides disclosed herein.

SEQ ID NOs: 15 through 174 are found in Figures 1, 2, 7, 15, 17, and 18.--

Column 9:

Line 63 "and Cry j 7"

should read

--and Cry j 2 --

Column 10:

Line 59 "are same"

should read

--are the same--

Column 11:

Line 13 "DQA10102/0301 --"

should read

--DQA1\*0102/0301 --

Column 11:

Line 16 "DPB10501/0402;"

should read

--DPB1\*0501/0402;--

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,719,976 B1  
APPLICATION NO. : 09/142524  
DATED : April 13, 2004  
INVENTOR(S) : Toshio Sone et al.

Page 4 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 11:  
Line 31 "CD8<sup>31</sup>"

should read

--CD8<sup>-</sup> --

Column 12:  
Line 14 "Cry j2 p118-195"

should read

--Cry j2 p181-195--

Column 12:  
Line 27 "mitomycin C of the"

should read

--mitomycin C or the --

Column 12:  
Line 53 "Identifying the Type of T Cell Clone"

should read

--Identifying the Th Type of T Cell Clone--

Column 13:  
Line 54 "C.A.#1. a-Arg-Arg-b-Arg-Arg-c-Arg-Arg-e-Arg-Arg"

should read

--C.A.#1. a-Arg-Arg-b-Arg-Arg-c-Arg-Arg-d-Arg-Arg-e --

Column 14:  
Line 14 "4-methylumbelliferyl-,  $\beta$ -D-galacto-pyranoside/0.01 M"

should read

--4-methylumbelliferyl- $\beta$ -D-galacto-pyranoside/0.01 M --

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,719,976 B1  
APPLICATION NO. : 09/142524  
DATED : April 13, 2004  
INVENTOR(S) : Toshio Sone et al.

Page 5 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 14:

Line 16 "NaN, and"

should read

--NaN<sub>3</sub> and--

Column 15:

Lines 38-39 "proliferation scintillation counter."

should read

--proliferation response (Fig. 10).--

Column 15:

Lines 40-43 "This paragraph is the same as the preceding paragraph."

should read

--This paragraph should not be repeated.--

Column 15:

Lines 40-43 "The peripheral lymphocytes from five out of six patients showed proliferation response to the multi-epitope peptide. The peripheral lymphocytes from one patient and two healthy subjects showed no proliferation response (FIG. 10)."

should read

--The proliferation response of peripheral lymphocytes began to occur with stimulation of 01. µg/ml of the multi-epitope peptide and increased dose-dependently. Based on the results, the concentration of the multi-epitope peptide required for inducing T cell proliferation response in vitro is at least 10µg/ml.--

Column 16:

Line 45 "spleen cells (5x10<sup>6</sup> cells) were cultured"

should read

--spleen cells were collected from three mice and mixed together. The spleen cells

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 6,719,976 B1  
APPLICATION NO. : 09/142524  
DATED : April 13, 2004  
INVENTOR(S) : Toshio Sone et al.

Page 6 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(5x10<sup>6</sup> cells)--

Column 18:

Line 48 "N. Hei 8-15327), or "

should read

--No. Hei 8-153527), or--

Column 20:

Line 30, Claim 3 "A peptide-based immunotherapeutic"

should read

-- A peptide-based immunotherapeutic --

Column 20:

Line 34, Claim 4 "carrier or diluent or diluent and"

should read

--carrier or diluent and--

Signed and Sealed this

Eighteenth Day of September, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looping initial "J" and a cursive "Dudas".

JON W. DUDAS  
*Director of the United States Patent and Trademark Office*